Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of “Moderate Buy” by Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $10.80.

Several research firms recently weighed in on XERS. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Barclays began coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $5.40 on Monday. Xeris Biopharma has a 1 year low of $3.81 and a 1 year high of $10.08. The firm’s fifty day simple moving average is $6.49 and its 200 day simple moving average is $7.35. The firm has a market capitalization of $931.13 million, a P/E ratio of -539.46 and a beta of 0.61. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. As a group, sell-side analysts predict that Xeris Biopharma will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the sale, the insider directly owned 1,685,426 shares in the company, valued at approximately $13,483,408. The trade was a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75. Following the completion of the sale, the insider directly owned 1,226,507 shares in the company, valued at approximately $7,665,668.75. The trade was a 1.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 89,908 shares of company stock worth $648,515 over the last 90 days. Corporate insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XERS. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the 4th quarter worth approximately $25,000. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma during the third quarter worth $35,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after buying an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.